nanoCLAMP potently neutralizes SARS-CoV-2 and protects K18-hACE2 mice from infection
Pagneux, Q.; Garnier, N.; Fabregue, M.; Sharkaoui, S.; Mazzoli, S.; Engelmann, I.; Boukherroub, R.; Strecker, M.; Cruz, E.; Ducos, P.; Zarubica, A.; Suderman, R.; Szunerits, S.
Show abstract
Intranasal treatments, combined with vaccination, has the potential to slow mutational evolution of virusues by reducing transmission and replication. Here we illustrate the development of a SARS-CoV-2 receptor binding domain (RBD) nanoCLAMP and demonstrate its potential as an intranasally administered therapeutic. A multi-epitope nanoCLAMP was made by fusing a pM affinity single-domain nanoCLAMP (P2710) to alternate epitope binding nanoCLAMP, P2609. The resulting multimerised nanoCLAMP P2712 had sub-pM affinity for the Wuhan and South African (B.1.351) RBD (KD < 1 pM), and decreasing affinity for the Delta (B.1.617.2) and Omicron (B.1.1.529) variants (86 pM and 19.7 nM, respectively). P2712 potently inhibited ACE2:RBD interaction, suggesting its utility as a therapeutic. With an IC50 = 0.4 {+/-} 0.1 nM obtained from neutralization experiments using pseudoviral particles as well as patient cultured SARS-CoV-2 samples, nanoCLAMP P2712 protected K18-hACE2 mice from SARS-CoV-2 infection, reduced viral loads in the lungs and brains, and reduced associated upregulation of inflammatory cytokines and chemokines. Together, our findings warrant further investigation into the development of nanoCLAMPs as effective intranasally delivered COVID19 therapeutics.
Matching journals
The top 16 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface 96%
- SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice 96%
- Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine 95%
Similar papers in this journal
- Tracing production instability in a clonally-derived CHO cell line using single cell transcriptomics 93%
- Production of Trimeric SARS-CoV-2 Spike Protein by CHO Cells for Serological COVID-19 Testing 92%
- High performance anion exchange chromatography purification of probiotic bacterial extracellular vesicles enhances purity and anti-inflammatory efficacy 92%
Similar papers in this journal
- A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants 96%
- Comparison of immunogenicity and protection efficacy of self-amplifying and circular mRNA vaccines for SARS-CoV-2 96%
- Quantitative Assays Reveal Cell Fusion at Minimal Levels of SARS-CoV-2 Spike Protein and Fusion-from-Without 95%
Similar papers in this journal
- Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological and pathological disease in a Syrian hamster model of COVID-19 97%
- A novel biparatopic antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy 96%
- Development of Potent and Effective Synthetic SARS-CoV-2 Neutralizing Nanobodies 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.